Montrose-Rafizadeh C - Search Results

1

The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist.

Krishnan V, Bullock HA, Yaden BC, Liu M, Barr RJ, Montrose-Rafizadeh C, Chen K, Dodge JA, Bryant HU. Krishnan V, et al. Mol Pharmacol. 2005 Mar;67(3):744-8. doi: 10.1124/mol.104.005272. Epub 2004 Nov 22. Mol Pharmacol. 2005. PMID: 15557561

2

Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.

Norman BH, Dodge JA, Richardson TI, Borromeo PS, Lugar CW, Jones SA, Chen K, Wang Y, Durst GL, Barr RJ, Montrose-Rafizadeh C, Osborne HE, Amos RM, Guo S, Boodhoo A, Krishnan V. Norman BH, et al. J Med Chem. 2006 Oct 19;49(21):6155-7. doi: 10.1021/jm060491j. J Med Chem. 2006. PMID: 17034120

3

A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia.

Sato M, Lu J, Iturria S, Stayrook KR, Burris LL, Zeng QQ, Schmidt A, Barr RJ, Montrose-Rafizadeh C, Bryant HU, Ma YL. Sato M, et al. J Bone Miner Res. 2010 Jun;25(6):1326-36. doi: 10.1002/jbmr.15. J Bone Miner Res. 2010. PMID: 20200930 Free article.

4

Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.

Xu Y, Mayhugh D, Saeed A, Wang X, Thompson RC, Dominianni SJ, Kauffman RF, Singh J, Bean JS, Bensch WR, Barr RJ, Osborne J, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Huang N, Luffer-Atlas D, Rungta D, Maise DE, Mantlo NB. Xu Y, et al. J Med Chem. 2003 Nov 20;46(24):5121-4. doi: 10.1021/jm034173l. J Med Chem. 2003. PMID: 14613314

5

Unique ligand binding patterns between estrogen receptor alpha and beta revealed by hydrogen-deuterium exchange.

Dai SY, Burris TP, Dodge JA, Montrose-Rafizadeh C, Wang Y, Pascal BD, Chalmers MJ, Griffin PR. Dai SY, et al. Biochemistry. 2009 Oct 13;48(40):9668-76. doi: 10.1021/bi901149t. Biochemistry. 2009. PMID: 19739677 Free PMC article.

6

Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method.

Dai SY, Chalmers MJ, Bruning J, Bramlett KS, Osborne HE, Montrose-Rafizadeh C, Barr RJ, Wang Y, Wang M, Burris TP, Dodge JA, Griffin PR. Dai SY, et al. Proc Natl Acad Sci U S A. 2008 May 20;105(20):7171-6. doi: 10.1073/pnas.0710802105. Epub 2008 May 12. Proc Natl Acad Sci U S A. 2008. PMID: 18474858 Free PMC article.

7

Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.

Richardson TI, Clarke CA, Yu KL, Yee YK, Bleisch TJ, Lopez JE, Jones SA, Hughes NE, Muehl BS, Lugar CW, Moore TL, Shetler PK, Zink RW, Osborne JJ, Montrose-Rafizadeh C, Patel N, Geiser AG, Galvin RJ, Dodge JA. Richardson TI, et al. Among authors: montrose rafizadeh c. ACS Med Chem Lett. 2010 Dec 9;2(2):148-53. doi: 10.1021/ml100220b. eCollection 2011 Feb 10. ACS Med Chem Lett. 2010. PMID: 24900294 Free PMC article.

8

Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design.

Hughes NE, Bleisch TJ, Jones SA, Richardson TI, Doti RA, Wang Y, Stout SL, Durst GL, Chambers MG, Oskins JL, Lin C, Adams LA, Page TJ, Barr RJ, Zink RW, Osborne H, Montrose-Rafizadeh C, Norman BH. Hughes NE, et al. Among authors: montrose rafizadeh c. Bioorg Med Chem Lett. 2016 Jul 15;26(14):3274-3277. doi: 10.1016/j.bmcl.2016.05.056. Epub 2016 May 20. Bioorg Med Chem Lett. 2016. PMID: 27261179

9

Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.

Hamdouchi C, Maiti P, Warshawsky AM, DeBaillie AC, Otto KA, Wilbur KL, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Cr S, Lineswala JP, Neathery GL, Bouaichi C, Diseroad BA, Campbell AN, Sweetana SA, Adams LA, Cabrera O, Ma X, Yumibe NP, Montrose-Rafizadeh C, Chen Y, Miller AR. Hamdouchi C, et al. Among authors: montrose rafizadeh c. J Med Chem. 2018 Feb 8;61(3):934-945. doi: 10.1021/acs.jmedchem.7b01411. Epub 2018 Jan 5. J Med Chem. 2018. PMID: 29236497

10

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).

Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, Wilbur KL, Lineswala JP, Piper JL, Coffey DS, Sweetana SA, Haas JV, Brooks DA, Pratt EJ, Belin RM, Deeg MA, Ma X, Cannady EA, Johnson JT, Yumibe NP, Chen Q, Maiti P, Montrose-Rafizadeh C, Chen Y, Reifel Miller A. Hamdouchi C, et al. Among authors: montrose rafizadeh c. J Med Chem. 2016 Dec 22;59(24):10891-10916. doi: 10.1021/acs.jmedchem.6b00892. Epub 2016 Nov 11. J Med Chem. 2016. PMID: 27749056

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters